Description
A potent antagonist of the LTB4 receptor, BLT1, that inhibits the specific binding of radiolabeled LTB4 to isolated human neutrophils (IC50 value of 17.6 nM); inhibits the LTB4-induced chemotaxis of human neutrophils (IC50 value of 6.3 nM)
Formal name: 2-[3-[3-[(5-ethyl-4′-fluoro-2-hydroxy[1,1′-biphenyl]4-yl)oxy]propoxy]-2-propylphenoxy]-benzoic acid
Synonyms: Etalocib|VML 295
Molecular weight: 544.6
CAS: 161172-51-6
Purity: ≥98%
Formulation: A solution in methyl acetate
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cancer|Cell Cycle|G2/S||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Lipid Biochemistry|Lipoxygenase Pathways